Considering chemotherapy in synovial sarcoma

Bibliography

• Ferrari A, Bisogno G, Meazza C, et al. The challenge of access to care for soft tissue sarcomas bridging pediatric and adult age: the Italian pediatric oncology view. Expert Rev Anticancer Ther 2012;12(2):243-54
   PubMed Web of Science ®Google Scholar
• Sultan I, Rodriguez-Galindo C, Saab R, et al. Comparing children and adults with synovial sarcoma in the surveillance, epidemiology and end results program, 1983 to 2005: an analysis of 1268 patients. Cancer 2009;115:3537-47
   PubMed Web of Science ®Google Scholar
• Ferrari A, Sultan I, Huang TT, et al. Soft tissue sarcoma across the age spectrum: a population-based study from the surveillance epidemiology and end results database. Pediatr Blood Cancer 2011;57:943-9
   PubMed Web of Science ®Google Scholar
• Ferrari A, Casanova M. New concepts for the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas. Expert Rev Anticancer Ther 2005;5(2):307-18
   PubMed Web of Science ®Google Scholar
• Ferrari A, De Salvo GL, Brennan B, et al. Synovial sarcoma in children and adolescents: the European pediatric soft tissue sarcoma study group prospective trial (EpSSG NRSTS 2005). Ann Oncol 2015;26:567-72
   PubMed Web of Science ®Google Scholar
• Kerouanton A, Jimenez I, Cellier C, et al. Synovial sarcoma in children and adolescents. J Pediatr Hematol Oncol 2014;36:257-62
   PubMed Web of Science ®Google Scholar
• Chotel F, Unnithan A, Chandrasekar CR, et al. Variability in the presentation of synovial sarcoma in children. A plea for greater awareness. J Bone Joint Surg Br 2008;90:1090-6
   PubMed Web of Science ®Google Scholar
• Papillard-Maréchal S, Brisse HJ, Pannier S, et al. Pseudotumoral soft tissue masses in children and adolescents. Arch Pediatr 2015;22:14-23
   PubMed Web of Science ®Google Scholar
• Guillou L, Benhattar J, Bonichon F, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: A multicenter, retrospective analysis. J Clin Oncol 2004;22:4040-50
   PubMed Web of Science ®Google Scholar
• Ren T, Lu Q, Guo W, et al. The clinical implication of SS18-SSX fusion gene in synovial sarcoma. Br J Cancer 2013;109:2279-85
   PubMed Web of Science ®Google Scholar
• Lagarde P, Przybyl J, Brulard C, et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol 2013;31:608-15
   PubMed Web of Science ®Google Scholar
• Canter RJ, Qin LX, Maki RG, et al. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res 2008;14:8191-7
   PubMed Web of Science ®Google Scholar
• Tamborini E, Bonadiman L, Greco A, et al. Expression of ligand-activated KIT and platelet-derived growth factor receptor β tyrosine kinase receptors in synovial sarcoma. Clin Cancer Res 2004;10:938-43
   PubMed Web of Science ®Google Scholar
• Thomas DG, Giordano TJ, Sanders D, et al. Expression of receptor tyrosine kinases growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 2005;103(4):830-08
   PubMed Web of Science ®Google Scholar
• Kawaguchi S, Wada T, Ida K, et al. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med 2005;3(1):1
   PubMed Web of Science ®Google Scholar
• Chibon F, Lagarde P, Salas S, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 2010;16:781-7
   PubMed Web of Science ®Google Scholar
• Chakiba C, Lagarde P, Pissaloux D, et al. Response to chemotherapy is not related to chromosome instability in synovial sarcoma. Ann Oncol 2014;25:2267-71
   PubMed Web of Science ®Google Scholar
• Przybyl J, Sciot R, Wozniak A, et al. Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features. Int J Biochem Cell Biol 2014;53:505-13
   PubMed Web of Science ®Google Scholar
• Charest M, Hickeson M, Lisbona R, et al. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur J Nucl Med Mol Imaging 2009;36:1944-51
   PubMed Web of Science ®Google Scholar
• Ferrari A, De Salvo GL, Oberlin O, et al. Synovial sarcoma in children and adolescents: A critical reappraisal of staging investigations in relation to the rate of metastatic involvement at diagnosis. Eur J Cancer 2012;48:1370-5
   PubMed Web of Science ®Google Scholar
• Harmer MH. TNM classification of pediatric Tumors. UICC International Union Against Cancer; Geneva: Switzerland: 1982. p. 23-8
   Google Scholar
• Maurer HM, Beltangady M, Gehan EA, et al. The intergroup rhabdomyosarcoma study I: a final report. Cancer 1988;61:209-20
   PubMed Web of Science ®Google Scholar
• Okcu MF, Munsell M, Treuner J, et al. Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J Clin Oncol 2003;21:1602-11
   PubMed Web of Science ®Google Scholar
• Ferrari A, Bisogno G, Alaggio G, et al. Synovial sarcoma of children and adolescents: the prognostic role of axial sites. Eur J Cancer 2008;44:1202-9
   PubMed Web of Science ®Google Scholar
• Ferrari A, Gronchi A, Casanova M, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 2004;101:627-34
   PubMed Web of Science ®Google Scholar
• Brecht IB, Ferrari A, Int-Veen C, et al. Grossly-resected synovial sarcoma treated by the German and Italian pediatric soft tissue sarcoma cooperative group: discussion on the role of adjuvant therapies. Pediatr Blood Cancer 2006;46:11-17
   PubMed Web of Science ®Google Scholar
• Brennan B, Stevens M, Kelsey A, Stiller CA. Synovial sarcoma in childhood and adolescence: a retrospective series of 77 patients registered by the children’s cancer and leukaemia group between 1991 and 2006. Pediatr Blood Cancer 2010;55:85-90
   PubMed Web of Science ®Google Scholar
• Orbach D, Dowell HM, Rey A, et al. Sparing strategy does not compromise prognosis in pediatric localized synovial sarcoma: experience of the international society of pediatric oncology, malignant mesenchymal tumors (SIOP-MMT) working group. Pediatr Blood Cancer 2011;57:1130-6
   PubMed Web of Science ®Google Scholar
• Stanelle EJ, Christison-Lagay ER. Pediatric and adolescent synovial sarcoma: Multivariate analysis of prognostic factors and survival outcomes. Ann Surg Oncol 2013;20:73-9
   PubMed Web of Science ®Google Scholar
• Lewis JJ, Antonescu CR, Leung DH, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumours of the extremity. J Clin Oncol 2000;18:2087-94
   PubMed Web of Science ®Google Scholar
• Trassard M, Le Doussal V, Hacene K, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol 2001;19:525-34
   PubMed Web of Science ®Google Scholar
• Spurrell EL, Fisher C, Thomas JM, Judson IR. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol 2005;16(3):437-44
   PubMed Web of Science ®Google Scholar
• Eilber FC, Brennan MF, Eilber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg 2007;246(1):105-13
   PubMed Web of Science ®Google Scholar
• Guadagnolo BA, Zagars GK, Ballo MT, et al. Long-term outcomes for synovial sarcoma treated with conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys 2007;69(4):1173-80
   PubMed Web of Science ®Google Scholar
• Italiano A, Penel N, Robin YM, et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol 2009;20(3):425-30
   PubMed Web of Science ®Google Scholar
• Palmerini E, Staals EL, Alberghini M, et al. Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer 2009;115(13):2988-98
   PubMed Web of Science ®Google Scholar
• Al-Hussaini H, Hogg D, Blackstein ME, et al. Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma. Sarcoma 2011;2011:231789
   PubMedGoogle Scholar
• Tarkan Y, Erkan A, Seber-Selcuk E, et al. Clinical and pathological features of patients with resected synovial sarcoma: A multicenter retrospective analysis of the anatolian society of medical oncology. J Cancer Res Ther 2014;10:73-8
   PubMed Web of Science ®Google Scholar
• Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997;350:1647-54
   PubMed Web of Science ®Google Scholar
• Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001;19:1238-47
   PubMed Web of Science ®Google Scholar
• Woll PJ, Reichardt P, Le Cesne A, et al. EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group Sarcoma Disease Site Committee. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 2012;13:1045-105
   PubMed Web of Science ®Google Scholar
• Gronchi A, Casali P. Adjuvant therapy for high-risk soft tissue sarcoma in the adult. Curr Treat Options Oncol 2013;14(3):415-24
   PubMed Web of Science ®Google Scholar
• Kampe CE, Rosen G, Eilber F, et al. Synovial sarcoma. A study of intensive chemotherapy in 14 patients with localized disease. Cancer 1993;72(7):2161-9
   PubMed Web of Science ®Google Scholar
• Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 1994;73(10):2506-11
   PubMed Web of Science ®Google Scholar
• Meazza C, Casanova M, Luksch R, et al. Prolonged 14-Day Continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma. Pediatr Blood Cancer 2010;55:617-20
   PubMed Web of Science ®Google Scholar
• Ferrari A, De Salvo GL, Dall’Igna P, et al. Salvage rates and prognostic factors after relapse in children and adolescents with initially localised synovial sarcoma. Eur J Cancer 2012;48:3448-55
   PubMed Web of Science ®Google Scholar
• Ferrari A, Miceli R, Rey A, et al. Non-metastatic unresected pediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. Eur J Cancer 2011;47:724-31
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Verderio P, Messina A, et al. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer 2012;118(23):5857-66
   PubMed Web of Science ®Google Scholar
• Soole F, Maupain C, Defachelles AS, et al. Synovial sarcoma relapses in children and adolescents: prognostic factors, treatment and outcome. Pediatr Blood Cancer 2014;61:1387-93
   PubMed Web of Science ®Google Scholar
• Ferrari A, Casanova M. Relapse in synovial sarcoma: what can be done for poor outcomes? Clinical Practice 2013;10(4):389-91
   Google Scholar
• Zwaan CM, Kearns P, Caron H, et al. The role of the innovative therapies for children with cancer (ITCC) European Consortium. Cancer Treat Rev 2010;36:328-34
   PubMed Web of Science ®Google Scholar
• Vassal G, Zwaan CM, Ashley D, et al. New drugs for children and adolescents with cancer: the need for novel development pathways. Lancet Oncol 2013;14:e117-24
   PubMed Web of Science ®Google Scholar
• Teng HW, Wang HW, Chen WM, et al. Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma. Surg Oncol 2011;103(8):773-81
   Web of Science ®Google Scholar
• Friedrichs N, Trautmann M, Endl E, et al. Phosphatidylinositol-3’-kinase/AKT signaling is essential in synovial sarcoma. Int J Cancer 2011;129(7):1564-75
   PubMed Web of Science ®Google Scholar
• Nakayama R, Mitani S, Nakagawa T, et al. Gene expression profiling of synovial sarcoma: distinct signature of poorly differentiated type. Am J Surg Pathol 2010;34(11):1599-607
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Le Cesne A, Whelan JS, et al. A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. Oncologist 2008;13(4):467-73
   PubMed Web of Science ®Google Scholar
• Yoo KH, Kim HS, Lee SJ, et al. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. BMC Cancer 2015;15(1):154
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer - soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009;27:3126-32
   PubMed Web of Science ®Google Scholar
• van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft tissue sarcoma (PALETTE): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379(9829):1879-86
   PubMed Web of Science ®Google Scholar
• Glade Bender JL, Lee A, Reid JM, et al. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children’s oncology group phase I consortium report. J Clin Oncol 2013;31(24):3034-43
   PubMed Web of Science ®Google Scholar
• Fox E, Aplenc R, Bagatell R, et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol 2010;28(35):5174-81
   PubMed Web of Science ®Google Scholar
• Hong D, Garrido-Laguna I, Ekmekcioglu S, et al. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer 2014;120(14):2164-73
   PubMed Web of Science ®Google Scholar
• Blay JY, Leahy MG, Nguyen BB, et al. Randomised phase III trial of trabectidin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer 2014;50(6):1137-47
   PubMed Web of Science ®Google Scholar
• Sanfilippo R, Dileo P, Blay JY, et al. Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. Anticancer Drugs 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Albritton KH, Randall RL. Prospects for targeted therapy of synovial sarcoma. J Pediatr Hematol Oncol 2005;27:219-22
   PubMed Web of Science ®Google Scholar
• Fukukawa C, Hanaoka H, Nagayama S, et al. Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci 2008;99(2):432-40
   PubMed Web of Science ®Google Scholar
• Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29(7):917-24
   PubMed Web of Science ®Google Scholar
• Maki RG, Jungbluth AA, Gnjatic S, et al. A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma 2013;2013:168145
   PubMedGoogle Scholar